SCHEMBL6318063

SCHEMBL6318063

CCc1ccc(-c2noc(N)c2C(=O)NCCCc2ccccc2)s1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.54
TSHR P16473 1/20 0.52
NPC1 O15118 4/20 0.46
RAB9A P51151 3/20 0.46
FAAH O00519 2/20 0.45
USP2 O75604 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
POLB P06746 2/20 0.43
GAA P10253 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
STAT3 P40763 1/20 0.43
TDP1 Q9NUW8 2/20 0.42
HPGD P15428 2/20 0.41
NLRP3 Q96P20 1/20 0.41
KDM4E B2RXH2 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
S1PR2 O95136 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6316150 0.97 L3MBTL1 (0.51) L3MBTL1TSHRNPC1RAB9AFAAH
SCHEMBL6317389 0.94 NPC1 (0.53) L3MBTL1TSHRNPC1RAB9AFAAH
SCHEMBL6315066 0.90 L3MBTL1 (0.59) L3MBTL1TSHRNPC1RAB9AFAAH
SCHEMBL6317805 0.88 GAA (0.48) L3MBTL1NPC1RAB9ASMN1; SMN2POLB
SCHEMBL6317722 0.87 CA1 (0.42) L3MBTL1TSHRNPC1RAB9ASMN1; SMN2
SCHEMBL6321492 0.87 L3MBTL1 (0.53) L3MBTL1TSHRNPC1RAB9AFAAH
SCHEMBL6324861 0.87 L3MBTL1 (0.55) L3MBTL1TSHRNPC1RAB9AFAAH
SCHEMBL6315932 0.86 ALOX15 (0.42) L3MBTL1NPC1RAB9ASMN1; SMN2GAA
SCHEMBL6317695 0.85 ALOX15 (0.43) L3MBTL1SMN1; SMN2GAAHPGDALDH1A1
SCHEMBL6321721 0.85 ALOX15 (0.43) L3MBTL1SMN1; SMN2GAAHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
CN-1549714-A Aminoisoxazole derivatives active as kinase inhibitors 2004-11-24 CN claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 L3MBTL1 4176/4885TSHR 3971/4885NPC1 3741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.